1

Lupin Limited

#1561

Rank

$11.32B

Marketcap

IN India

Country

Lupin Limited
Leadership team

Ms. Vinita D. Gupta (CEO & Exec. Director)

Mr. Nilesh Deshbandhu Gupta (MD & Exec. Director)

Mr. Ramesh Swaminathan (Global CFO, Head Corp. Affairs & Exec. Director)

Products/ Services
Biotechnology, Manufacturing, Pharmaceutical
Number of Employees
1,000 - 20,000
Headquarters
Mumbai, Maharashtra, India
Established
1968
Net Income
20M - 100M
Revenue
Above - 1B
Traded as
LUPIN.NS
Social Media
Overview
Location
Summary
Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women's health, and anti-tuberculosis. The company is also involved in the provision of biosimilar and over-the-counter products; specialty products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities. Lupin Limited network consists of 18 labs, 280 LupiMitra collection centers, and 450 pick-up points. It operates in India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
History

Lupin Ltd was founded in 1968 by Dr. Desh Bandhu Gupta. Lupin's mission is to continually develop and bring out the best in each of its people while contributing to the health, wealth and well-being of numerous individuals, families and communities.

Mission
To put India and the world at the forefront of the global pharmaceutical industry by providing meaningful and innovative healthcare solutions for all of the stakeholders in the healthcare value chain.
Vision
To create global health care through breakthroughs in technology, by partnering with research and academic organizations and leveraging a diverse portfolio of therapeutic and specialty products.
Key Team

Mr. Johnny Mack Mikell (Pres & Global Head of Quality)

Dr. Hemant Bakhru (VP of Investor Relations and M&A)

Mr. Sreeji Gopinathan (Chief Information Officer)

Dr. Sofia Mumtaz (Pres of Legal and Compliance of Australia, Japan & Canada Bus.)

Dr. Shahin Fesharaki (Pres - Global Chief Scientific Officer)

Ms. Diana Amador-Toro (Sr. VP of Global Compliance)

Ms. Shweta Munjal (VP & Global Head ? Corp. Communications and Head of Sustainability)

Recognition and Awards
Lupin Ltd has earned many awards over the years, including numerous awards from CII, Good Pharmaceutical Management Awards , India Pharma Awards, Drug Today- Pharma Leaders Survey, and many other prestigious awards.
References
Lupin Limited
Leadership team

Ms. Vinita D. Gupta (CEO & Exec. Director)

Mr. Nilesh Deshbandhu Gupta (MD & Exec. Director)

Mr. Ramesh Swaminathan (Global CFO, Head Corp. Affairs & Exec. Director)

Products/ Services
Biotechnology, Manufacturing, Pharmaceutical
Number of Employees
1,000 - 20,000
Headquarters
Mumbai, Maharashtra, India
Established
1968
Net Income
20M - 100M
Revenue
Above - 1B
Traded as
LUPIN.NS
Social Media